SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Dermorphin	Cerebrolysin	Selank
Research Topic	Clinical / Endocrine Pharmacology	Neuro / Cognitive Research	Neuro / Cognitive Research
Pharmacology	Experimental opioid peptide	Peptide / amino-acid hydrolysate mixture	Synthetic tuftsin-related regulatory heptapeptide; registered nasal medicine in Russia
PrimeCore Class	Class BInvestigational	Class AApproved in a bounded context	Class AApproved in a bounded context
Evidence Grade	Grade EPreclinical evidence	Grade CEarly human evidence	Grade CEarly human evidence
Evidence boundary	Dermorphin is classified here as Experimental opioid peptide. Published literature is dominated by receptor, animal and analytical work rather than verified therapeutic trials of a catalogue product. No FDA-approved dermorphin medicine was identified in this review; WADA prohibits narcotics in competition and non-approved substances may also fall under S0. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions.	Cerebrolysin is a peptide/amino-acid hydrolysate mixture, not a single sequence-defined peptide. The 1,070-patient CASTA trial had a neutral primary outcome; post-hoc severe-stroke signals do not replace it. The exploratory CARS rehabilitation trial reported a positive arm-function outcome and called for larger confirmation. A dated Thai product record exists, but does not authenticate the supplier vial or establish general cognitive enhancement.	A tuftsin-related heptapeptide with Russia-specific product history and limited human evidence; it is not FDA-approved.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	replication in adequately powered blinded placebo-controlled trials long-term safety, immunogenicity and rare adverse events comparability of free peptide, diacetate, nasal drops and compounded formulations clinical significance of resting-state functional-connectivity changes efficacy for healthy cognition, sleep, depression or non-label uses current marketing-authorisation status in Thailand, the United States, European Union and United Kingdom
Limitations	Dermorphin molecule or active moiety ≠ ester/salt ≠ formulation ≠ brand ≠ supplier product; biological plausibility or historical use ≠ current approval ≠ safe performance use	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ข้อมูล acute stroke ไม่เท่ากับประสิทธิผลในความจำเสื่อมทุกสาเหตุ และบทความนี้ไม่ใช้แทนการรักษา stroke มาตรฐานหรือการฟื้นฟู	The evidence base is geographically concentrated and many clinical articles are available primarily as short English abstracts. Comparator studies often lack placebo controls or enough methodological detail to assess bias. Registered-product claims come from a Russia-specific label and manufacturer materials. Formulation, route and sequence differences limit transfer to compounded or research products.
Sources	NIH PubChem · Dermorphin identity record FDA · Bodybuilding and steroid-like product safety warning WADA · 2026 Prohibited List	Thai FDA · CEREBROLYSIN 1C 43/32 · data dated 30 June 2025 CASTA · PMID 22282884 CARS · PMID 26564102	https://www.lsgeotar.ru/drugs/selank-AGJ2/attachments https://selank.ru/files/o-selanke/instruktsiya/%D0%98%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D0%B8%D1%8F%20%D0%BF%D0%BE%20%D0%BC%D0%B5%D0%B4%D0%B8%D1%86%D0%B8%D0%BD%D1%81%D0%BA%D0%BE%D0%BC%D1%83%20%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D0%B5%D0%BD%D0%B8%D1%8E%20%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE%20%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%B0%20%D0%A1%D0%B5%D0%BB%D0%B0%D0%BD%D0%BA.pdf https://precision.fda.gov/ginas/app/ui/substances/d1af04cb-96d7-4c14-975d-4fff76d66847 https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://pubmed.ncbi.nlm.nih.gov/18454096/ https://pubmed.ncbi.nlm.nih.gov/25176261/ https://pubmed.ncbi.nlm.nih.gov/26356395/ https://pubmed.ncbi.nlm.nih.gov/32342318/ https://pubmed.ncbi.nlm.nih.gov/11550013/ https://pubmed.ncbi.nlm.nih.gov/30255741/ https://pubmed.ncbi.nlm.nih.gov/28280289/ https://pubmed.ncbi.nlm.nih.gov/31625062/ https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://products.mhra.gov.uk/
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.